Growth and neuroendocrine dysfunction following therapy for childhood cancer.
Poor linear growth and short adult stature are common complications following successful treatment of childhood cancer. Although several factors contribute to the impaired growth of these patients, growth potential is most reduced following radiotherapy to the head or spine. Younger age at treatment and female sex seem to be significant and independent risk factors for short adult height. Early diagnosis and timely therapy of the endocrine sequelae of cancer treatment (i.e., GH deficiency, hypothyroidism, and precocious puberty) ensure that these individuals will reach their optimum growth potential. For patients exposed to high-dose radiotherapy (> 35-40 Gy) to the region of the hypothalamus and pituitary gland, a variety of neuroendocrine abnormalities in addition to GH deficiency and early sexual development may occur, including deficiencies of LH/FSH, TSH, and ACTH as well as hypersecretion of prolactin. Because these problems may develop many years after irradiation, patients at risk for neuroendocrine disturbances require long-term endocrine follow-up.
Sklar
C A
CA
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
D000328:Adult; D000359:Aftercare; D002648:Child; D004700:Endocrine System Diseases / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D005260:Female; D006130:Growth Disorders / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000628:therapy*; D012307:Risk Factors